Cover Image
Market Research Report

Global Glioma Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 762865
Published Content info 114 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Glioma Therapeutics Market 2019-2023
Published: December 14, 2018 Content info: 114 Pages
Description

About this market

Strategic alliances to drive growth in the market. Pharmaceutical companies are collaborating to develop medications for the treatment of glioma. These alliances can enhance R&D activities for new drugs for the treatment of glioma. Technavio' s analysts have predicted that the glioma therapeutics market will register a CAGR of more than 9% by 2023.

Market Overview

Expected approval of late-stage pipeline molecules

As the market is currently experiencing an acute lack of approved therapies, these late-stage pipeline molecules can tap into this unmet demand from the glioma patient pool. Once these molecules are launched during the forecast period, the global glioma therapeutics market should observe strong value growth from these newly launched therapeutics.

Availability of alternative therapies

Despite the availability of medications for the treatment of the glioma, there are several alternative procedures. The high cost, side effects, and long duration of treatment with the available medications are increasing patients' inclination toward the surgical and radiation treatment options.

For the detailed list of factors that will drive and challenge the growth of the glioma therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including NextSource Biotechnology and Novartis the competitive environment is quite intense. Factors such as the expected approval of late-stage pipeline molecules and the strategic alliances, will provide considerable growth opportunities to glioma therapeutics manufactures. F. Hoffmann-La Roche, Merck Sharp & Dohme, Mylan, NextSource Biotechnology, and Novartis are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR30499

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Small molecules - Market size and forecast 2018-2023
  • Biologics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Mylan
  • NextSource Biotechnology
  • Novartis

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global oncology therapeutics market
  • Exhibit 03: Segments of global oncology therapeutics market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Small molecules - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Small molecules - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in Americas
  • Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in EMEA
  • Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in APAC
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Decision framework
  • Exhibit 40: Some of the therapeutics that received orphan drug designation from the US FDA are mentioned below
  • Exhibit 41: Impact of drivers and challenges
  • Exhibit 42: Vendor landscape
  • Exhibit 43: Landscape disruption
  • Exhibit 44: Vendors covered
  • Exhibit 45: Vendor classification
  • Exhibit 46: Market positioning of vendors
  • Exhibit 47: F. Hoffmann-La Roche - Vendor overview
  • Exhibit 48: F. Hoffmann-La Roche - Business segments
  • Exhibit 49: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 50: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 51: F. Hoffmann-La Roche - Segment focus
  • Exhibit 52: F. Hoffmann-La Roche - Key offerings
  • Exhibit 53: F. Hoffmann-La Roche - Key customers
  • Exhibit 54: Merck Sharp & Dohme - Vendor overview
  • Exhibit 55: Merck Sharp & Dohme - Business segments
  • Exhibit 56: Merck Sharp & Dohme - Organizational developments
  • Exhibit 57: Merck Sharp & Dohme - Geographic focus
  • Exhibit 58: Merck Sharp & Dohme - Segment focus
  • Exhibit 59: Merck Sharp & Dohme - Key offerings
  • Exhibit 60: Merck Sharp & Dohme - Key customers
  • Exhibit 61: Mylan - Vendor overview
  • Exhibit 62: Mylan - Business segments
  • Exhibit 63: Mylan - Organizational developments
  • Exhibit 64: Mylan - Geographic focus
  • Exhibit 65: Mylan - Key offerings
  • Exhibit 66: Mylan - Key customers
  • Exhibit 67: NextSource Biotechnology - Vendor overview
  • Exhibit 68: NextSource Biotechnology - Organizational developments
  • Exhibit 69: NextSource Biotechnology - Key offerings
  • Exhibit 70: NextSource Biotechnology - Key customers
  • Exhibit 71: Novartis - Vendor overview
  • Exhibit 72: Novartis - Business segments
  • Exhibit 73: Novartis - Organizational developments
  • Exhibit 74: Novartis - Geographic focus
  • Exhibit 75: Novartis - Segment focus
  • Exhibit 76: Novartis - Key offerings
  • Exhibit 77: Novartis - Key customers
  • Exhibit 78: Validation techniques employed for market sizing
  • Exhibit 79: List of abbreviations
Back to Top